deng yue

Criou um novo artigo

1 C

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications. | #met #cancer #great

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications.

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications.

Luvometinib is an oral small molecule drug that belongs to the MET kinase inhibitor class. It is mainly used to treat patients with tumors carrying specific gene mutations, such as advanced or metastatic cancers in non-small cell lung cancer (NSCLC) driven by MET exon14 skipping mutations.

Curtir

Comentario

Compartilhar

Mudou sua imagem de perfil

1 C

Curtir

Comentario

Compartilhar

Carregar mais posts

Info

2 Postagens
Mulher
12/20/03
Morando em China

álbuns

(0)

(0)

(1)

rajesh sharma

Curtiu

(0)

Grupos

(0)